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Abstract
Evidence has suggested that insulin resistance (IR) or high levels of glucocorticoids (GCs) may be linked with the
pathogenesis and/or progression of Alzheimer’s disease (AD). Although studies have shown that a high level of GCs results
in IR, little is known about the molecular details that link GCs and IR in the context of AD. Abnormal phosphorylation of tau
and activation of m-calpain are two key events in the pathology of AD. Importantly, these two events are also related with
GCs and IR. We therefore speculate that tau phosphorylation and m-calpain activation may mediate the GCs-induced IR. Akt
phosphorylation at Ser-473 (pAkt) is commonly used as a marker for assessing IR. We employed two cell lines, wild-type
HEK293 cells and HEK293 cells stably expressing the longest human tau isoform (tau-441; HEK293/tau441 cells). We
examined whether DEX, a synthetic GCs, induces tau phosphorylation and m-calpain activation. If so, we examined whether
the DEX-induced tau phosphorylation and m-calpain activation mediate the DEX-induced inhibition on the insulin-
stimulated Akt phosphorylation. The results showed that DEX increased tau phosphorylation and induced tau-mediated m-
calpain activation. Furthermore, pre-treatment with LiCl prevented the effects of DEX on tau phosphorylation and m-calpain
activation. Finally, both LiCl pre-treatment and calpain inhibition prevented the DEX-induced inhibition on the insulin-
stimulated Akt phosphorylation. In conclusion, our study suggests that the tau phosphorylation and m-calpain activation
mediate the DEX-induced inhibition on the insulin-stimulated Akt phosphorylation.
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Introduction
Insulin resistance (IR) is defined as a state in which normal
amounts of insulin produce a subnormal biological response [1].
Binding of insulin to the insulin receptor promotes Akt
phosphorylation (and activation) at Ser-473 (pAkt) [2]. Inhibition
on the insulin-stimulated Akt phosphorylation is commonly used
as a marker of IR [2]. IR is a feature of type 2 diabetes mellitus
(DM2) and is involved in a wide spectrum of other clinical diseases.
It is increasingly recognized that IR may be linked with
Alzheimer’s disease (AD) [3,4]. For instance, clinical investigations
suggest that IR may occur before the onset of mild cognitive
impairment (MCI) and may be a marker of AD risk [5,6].
Moreover, rodent studies show that IR increases tau phosphor-
ylation and b-amyloid production, two hallmarks of AD pathology
[7,8]. Furthermore, IR exacerbates memory deficits in transgenic
mouse models of AD [9,10]. Hence, these studies have led to the
qualification of AD as ‘an insulin-resistant brain state’. However,
little is known about the pathogenic mechanisms that impair
insulin action in the context of AD.
Glucocorticoids (GCs) are well known to induce IR in a variety
of clinical and experimental settings [11]. In chronic IR and DM2,
the concentration of circulating GCs increases. AD patients may
also have higher plasma GCs levels than normal controls [12]. A
high level of GCs has been shown to result in impaired synaptic
plasticity, decreased neurogenesis and hippocampal atrophy,
thereby yielding memory deficits [13,14]. It is thus suggested that
there may be a link between a high level of GCs and AD
pathogenesis [12,13,14]. Although a high level of GCs is a
confounding factor in both IR and AD, little is known about the
molecular link between GCs and IR in the context of AD.
Tau hyperphosphorylation is one of the hallmark pathological
alterations in AD [15]. Tau is a microtubule-stabilizing protein
and supports the microtubule system responsible for intracellular
transport, axonal morphology and cell physiology. Tau hyperpho-
sphorylation occurs long before the onset of AD symptoms and
may play a crucial role in neurodegeneration in AD [15,16].
Although it has been suggested that tau hyperphosphorylation
may contribute independently to AD pathogenesis and/or
progression [17,18], little is known about the molecular mecha-
nisms underlying tau-mediated toxicities. Because both GCs and
IR have been shown to lead to tau hyperphosphorylation [19,20],
it is reasonable to postulate that GCs and IR may be linked by tau.
We have previously shown that tau might mediate the GCs-
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response element binding protein in HEK293 cells stably
expressing the longest human tau isoform (tau-441; HEK293/
tau441 cells) [21]. We were interested to examine whether tau
mediates the GCs-induced IR.
Calpains, a family of calcium-activated cysteine proteases, have
been reported to be involved in the pathogenesis of AD [22,23].
Our previous work and other studies have shown that m-calpain
(also called calpain 1) of the calpains family may play a significant
role in AD [24,25]. Dysregulation of calpains is also associated
with the risk of IR and DM2 [26,27,28,29]. Although many
studies have focused on calpain 10, more recent evidence also
highlights the role of m-calpain in IR and DM2 [30,31]. Moreover,
activation of m-calpain is also implicated in the GCs-induced
toxicities in muscles and brains [32,33]. We thus assumed that
GCs and IR may be also linked by m-calpain. It has been shown
that activation of m-calpain mediates the tau-induced toxicities in
rats cortical neurons over-expressing human tau [34]. We thus
wanted to examine whether m-calpain also mediates the GCs-
induced IR, and if so, whether m-calpain is linked with tau.
To address the issues mentioned above, we employed two cell
lines, wild-type HEK293 cells HEK293/tau441 cells, a good
cellular model to study tau pathology [35,36]. We examined
whether DEX, a synthetic GCs, inhibits the insulin-stimulated Akt
phosphorylation and if so, whether tau or m-calpain is involved in
the inhibitory effect of DEX. In HEK293/tau441 cells, we made
the following observations. 1) DEX increases tau phosphorylation
and induces tau-mediated m-calpain activation. 2) The effects of
DEX on tau phosphorylation and m-calpain activation are
prevented by LiCl pre-treatment. 3) Either LiCl pre-treatment
or calpain inhibition prevents the DEX-induced inhibition on the
insulin-stimulated Akt phosphorylation.
Materials and Methods
1. Antibodies and chemicals
Mouse monoclonal antibody (mAb) against b-actin was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Rabbit mAb against Akt and phosphorylated Akt at Ser473
(pAkt) were obtained from Cell Signaling Technology (Beverly,
MA, USA). Mouse mAb against m-calpain was purchased from
Sigma (St. Louis, MO, USA). Mouse mAb against Tau-1 was
obtained from Millipore (Billerica, MA, USA). The antibody
R134d that recognizes total tau was generously provided by Gong
Cheng-Xin (NYS Institute for Basic Research, SI, NY, USA).
Dexamethasone (DEX), insulin, mifepristone (RU), lithium
chloride (LiCl) and E-64d (calpain inhibitor) were purchased from
Sigma (St. Louis, MO, USA).
2. Cell lines, culture and treatment
HEK293 cells stably transfected with the longest isoform of
recombinant human tau (tau441; HEK293/tau441) and HEK293
cells transfected with an empty vector (HEK293/vec) were a
generous gift from Professor Qing Tian (Department of Patho-
physiology, Tongji Medical College, Huazhong University of
Science and Technology). The construction of HEK293/tau441
and HEK293/vec cells is as previously described [35,36]. For
control purposes, wild-type HEK293 cells were used and
compared with HEK293/vec cells; no differences between the
two cell lines were found. Both wild-type HEK293 and HEK293/
tau441 were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Eggenstein, Germany), supplemented with
10% (v/v) fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA)
and maintained in 37uC and 5% CO2.
For the experiments, both HEK293/tau441 and wild-type
HEK293 cells were first incubated in DMEM with 2% FBS
overnight in order to reduce the serum effects. The cells were then
pre-treated with RU (20 mM, 30 minutes), LiCl (10 mM, 1 hour),
or E-64d (30 mg/ml, 1 hour) and then treated with DEX (1 mM),
or treated with DEX (1 mM) alone. For treatment longer than
three days, the medium was changed at 72 hours (h) after exposure
to DEX. Then RU (20 mM), LiCl (10 mM) or E-64d (30 mg/ml)
with DEX (1 mM) or DEX (1 mM) were added to the media. After
incubation with the above agents, cells were exposed to 100 nM
insulin for 15 minutes (min) and then harvested for Western
blotting.
3. Western blotting
The total proteins from the cultures were extracted with the ice-
cold buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, 100 mM
sodium orthovanadate, 1 mM phenylmethysulfonyl fluoride and
1 mg/ml protease inhibitor cocktail (Beyotime Biotechnology,
Haimen, Jiangsu, China). The cell lysates were boiled, briefly
sonicated and centrifuged at 125006g for 15 min. The protein
concentration in each lysate was determined using a bicinochonic
acid (BCA) Protein Assay Kit (Beyotime Biotechnology, Haimen,
China) with the bovine serum albumin as the standard. Equal
amounts of proteins (60–80 mg) were separated on 10% SDS-
polyacrylamide gel (SDS-PAGE) and transferred to nitrocellulose
membranes. The membranes were blocked in 5% nonfat milk in
TTBS (10 mM Tris-HCl, 150 mM NaCl, 0.02% Tween-20,
pH 7.5) and probed overnight at 4uC with antibodies against b-
actin (1:400), pAkt, Akt, Tau-1 and m-calpain (1:1000) and total
tau (R134d, 1:10 000). The blots were developed with horseradish
peroxidase-conjugated secondary anti-mouse (1: 1000; Thermo
scientific, Rockford, IL, USA) or anti-rabbit antibodies (1: 3000;
Signalway antibody, Pearland, TX, USA) and visualized with an
enhanced chemiluminescent substrate kit (Thermo scientific,
Rockford, IL, USA) and exposure to CL-XPosure film (Kodak).
The films were scanned and the density of each of band was
quantified using Kodak Digital Science 1D software (Eastman
Kodak Co., New Haven, CT).
4. Statistical analysis
Numerical data were expressed as group means 6 SEM and
analyzed with SPSS statistical software (version 13.0). All data sets
were subjected to one-way ANOVA before application of post hoc
pair-wise comparisons. P,0.05 or lower was considered to
represent statistically significant differences.
Results
1. DEX induces inhibition on the insulin-stimulated Akt
phosphorylation in wild-type HEK293 and HEK293/
tau441 cells
The insulin-stimulated increase in pAkt is a key event in the
proximal insulin signalling pathway and the pAkt/Akt ratio has
been widely used as a marker for evaluating IR [2]. We therefore
determined whether GCs induce IR by examining the insulin-
stimulated Akt phosphorylation (pAkt/Akt ratio) in wild-type
HEK293 and HEK293/tau441 cells. Dexamethasone (DEX), a
synthetic GCs and specific glucocorticoid receptor (GR) agonist,
was used in our study as GCs. The concentration of DEX was
1 mM because it is in the range of the amount given for the
therapeutic purpose in clinical practice (e.g., dexamethasone
suppression test, prevention of respiratory distress in preterm
infants) and also applied for induction of long-term stress [37,38].
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lines (see Materials and Methods) to mimic the induction of long-term
stress in vivo [37,39]. Representative immunoblots from the results
obtained on the third day (D3) and on the sixth day (D6) after
DEX treatment were shown in Fig. 1. As shown in Fig. 1, total
amounts of Akt remained stable under the conditions and were
used as internal standards for measurement of Akt phosphoryla-
tion. Under basal conditions, insulin induced similar increases in
pAkt in both cell lines (lane 2 and 6, Fig. 1A). This suggests that in
HEK293/tau441 cells, the exogenously expressed tau by itself
does not affect the insulin-stimulated Akt phosphorylation.
Treatment with DEX alone did not affect the basal pAkt levels
in either of the two cell lines (lane 3 and 7, Fig. 1A). In wild-type
HEK293 cells, the inhibitory effect of DEX was not evident until
D6 (D6, lane 4, Fig. 1A). In HEK293/tau441 cells, the inhibitory
effect of DEX occurred on D3 (D3, lane 8, Fig. 1A) and then
sustained on day 4, day 5 (data not shown) and D6 (D6, lane 8,
Fig. 1A). We thus chose D3 and D6 as two representative time
points for the following experiments.
There two types of receptors that GCs can bind with, one is
glucocorticoid receptor (GR) and the other is mineralcorticoid
receptor (MR). Because HEK293 cells do not express MR [40], we
only used mifepristone (RU), a GR antagonist. Representative
immunoblots from wild-type HEK293 cells on D6 and those from
HEK293/tau441 cells on D3 were shown in Fig. 1B. Without
insulin stimulation, pre-treatment with RU (20 mM, 30 min; see
Materials and Methods) did not affect the pAkt levels upon DEX
treatment (lane 3, Fig. 1B). However, pre-treatment with RU
prevented the inhibitory effects of DEX in both cell lines (lane 4,
Fig. 1B), indicating that the inhibitory effect of DEX is mediated
by the GR.
Although DEX inhibited the insulin-stimulated Akt phosphor-
ylation in wild-type HEK293 and HEK293/tau441 cells, the
inhibitory effect of DEX occurred earlier in HEK293/tau441 cells
(D3 versus D6). Because GCs are known to induce tau
phosphorylation [14], we speculate that it is the DEX-induced
increase in tau phosphorylation that causes the difference
described above.
2. DEX increases tau phosphorylation in HEK293/tau441
cells, which is prevented by lithium chloride
We next assessed whether DEX increases tau phosphorylation
in HEK293/tau441 cells, and if so, whether lithium choride
(LiCl), an inhibitor of glycogen synthase kinase-3b (GSK-3b) that
has been shown to inhibit tau hyperphosphorylation in different
contexts [41,42,43], can prevent the action of DEX. To this end,
Western blots were performed using Tau-1 and R134d antibodies.
Tau-1 is an antibody that recognizes tau when it is dephosphor-
ylated within the epitope 189–207 [44]. R134d is an antibody that
recognizes total tau. HEK293/tau441 cells were pre-treated with
LiCl (10 mM, 1 h) and then treated with DEX (see Materials and
Methods) for 3 days (D3) or 6 days (D6). Total amounts of tau
(detected by R134d) remained stable under the conditions and
were used as internal standards for measurement of the relative
level of Tau-1 (Tau-1/R134d ratio, Fig. 2). As expected, DEX
Figure 1. Effects of dexamethasone on the insulin-stimulated
Akt phosphorylation. A): Both wild-type HEK293 and HEK293/tau441
cells were treated with 1 mM dexamethasone (DEX) for 1–6 days and
then stimulated with 100 nM insulin (i) for 15 min. Representative
immunoblots from the results on the third day (D3) and the sixth day
(D6) after DEX treatment were shown. Bars representing means 6 SEM
were shown below. Total amounts of Akt remained stable under the
conditions. In HEK293/tau441 cells, DEX prevented the insulin-
stimulated increases in pAkt on D3 and D6. In wild-type HEK293 cells,
the inhibitory effect of DEX was evident on D6 but not on D3. Each
experiment was repeated three times unless stated otherwise.
*P,0.05
versus control. B): Culture cells were pre-treated with mifepristone (RU;
20 mM, 30 min) and then treated with DEX for 3 days or 6 days.
Representative immunoblots from wild-type HEK293 cells on D6 and
those from HEK293/tau441 cells on D3 were shown, with bars
representing means 6 SEM below. Pre-treatment with RU prevented
the inhibitory effects of DEX.
*P,0.05 versus DEX group.
doi:10.1371/journal.pone.0035783.g001
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by the decrease in the level of Tau-1 (lane 2, Fig. 2). However,
DEX did not affect the Tau-1 level on D6 (lane 6, Fig. 2). LiCl
treatment alone did not affect basal Tau-1 levels (lane 3 and 7,
Fig. 2). However, pre-treatment with LiCl prevented the DEX-
induced decrease in Tau-1 on D3 (lane 4, Fig. 2), suggesting that
the DEX-induced increase in tau phosphorylation is prevented by
LiCl. Interestingly, although LiCl is widely accepted as an
inhibitor to GSK-3b [41], GSK-3b activity, measured by the
ratio of the phosphorylated GSK-3b at Ser-9 (p GSK-3b) and total
GSK-3b, was not obviously affected by DEX in HEK293/tau441
cells on D3 (data not shown). DEX actually decreased GSK-3b
activity (an increase in pGSK-3b/GSK-3b ratio) in wild-type
HEK293 cells on D3 (data not shown). The mechanisms
responsible for the effects of DEX and LiCl on tau phosphory-
lation in our system warrants further research. Nevertheless,
results described above show that LiCl pre-treatment prevents the
DEX-induced increase in tau phosphorylation in HEK293/
tau441 cells.
3. Insulin does affect tau phosphorylation in HEK293/
tau441 cells
We have shown that LiCl prevented the DEX-induced increase
in tau phosphorylation in HEK293/tau441 cells. To test our
hypothesis that the DEX-induced increase in tau phosphorylation
mediates the inhibition on the insulin-stimulated Akt phosphor-
ylation, we should examine whether LiCl corrects the inhibitory
effects of DEX. However, before that we also wanted to see how
insulin affects tau phosphorylation because previous studies
demonstrated that insulin could induce either tau phosphorylation
or dephosphorylation [45,46,47]. Moreover, insulin is well known
to activate the Akt/GSK-3b signaling pathway and thus inhibits
the activity of GSK-3b [45,46]. Because we have shown GSK-3b
inhibition by LiCl prevented the DEX-induced tau phosphoryla-
tion (Fig. 2), we examined the effect of insulin on tau
phosphorylation. HEK293/tau441 cells were pre-treated with
LiCl (10 mM, 1 h) and then treated with DEX (see Materials and
Methods) for 3 days (D3), followed by insulin stimulation. Total
amounts of tau remained stable under the conditions (Fig. 3).
Insulin stimulation under basal condition did affect the Tau-1 level
(lane 2, Fig. 3). Upon treatment with LiCl or co-treatment with
DEX and LiCl, insulin did not affect Tau-1 levels either (lane 6
and 8, Fig. 3). Importantly, insulin did not prevent the DEX-
induced decrease in Tau-1 (lane 4, Fig. 3). These results suggest
that insulin stimulation, at least in our system, does not affect tau
phosphorylation.
4. Lithium chloride prevents the DEX-induced inhibition
on the insulin-stimulated Akt phosphorylation in
HEK293/tau441
We have shown that LiCl prevented the DEX-induced increase
in tau phosphorylation and insulin did not affect tau phosphor-
ylation. We next examined whether LiCl corrects the DEX-
induced inhibition on the insulin-stimulated Akt phosphorylation
in HEK293/tau441 cells. However, it has also been reported that
Figure 2. Effects of DEX and lithium chloride on tau phosphor-
ylation. HEK293/tau441 cells were pre-treated with lithium chloride
(LiCl; 10 mM, 1 h) and then treated with DEX for 3 days (D3) or 6 days
(D6), followed by Western blotting analysis of tau phosphorylation with
Tau-1 (against dephosphorylated tau within the epitope 189–207) and
R134d (against total tau) antibodies. Total amounts of tau remained
largely stable and the level of tau phosphorylation was determined by
the Tau-1/R134d ratio. Bars representing means 6 SEM. On D3, DEX
induced an increase in tau phosphorylation, as evidenced by the
decrease in the Tau-1/R134d ratio. Pre-treatment with LiCl prevented
the effect of DEX on tau phosphorylation on D3.
*P,0.05 versus control,
#P,0.05 between indicated groups.
doi:10.1371/journal.pone.0035783.g002
Figure 3. Effects of insulin on tau phosphorylation. HEK293/
tau441 cells were pre-treated with LiCl (10 mM, 1 h) and then treated
with DEX for 3 days, followed by stimulation of insulin for 15 min and
Western analysis of Tau-1 and R134d. Bars representing means 6 SEM.
Insulin did not prevent the DEX-induced decrease in Tau-1 or affected
Tau-1 levels under other conditions, suggesting that insulin does not
affect tau phosphorylation.
*P,0.05 versus control.
doi:10.1371/journal.pone.0035783.g003
Tau, m-Calpain and Akt Phosphorylation
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35783LiCl affected insulin signaling through tau-independent mecha-
nisms [48]. We therefore also examined how LiCl affects the
insulin-stimulated Akt phosphorylation in wild-type HEK293 cells.
Both cell lines were treated with LiCl, DEX, or in combination of
them for 3 days (D3) or 6 days (D6). In both cell lines, LiCl did not
have obvious effects on pAkt levels under basal conditions, under
insulin stimulation alone or upon DEX treatment alone (lane 5, 6
and 7, Fig. 4). LiCl prevented the inhibitory effect of DEX in
HEK293/tau441 cells on D3 (HEK293/tau441, lane 8, Fig. 4A).
However, on D6, when the inhibitory effects of DEX were evident
in both cell lines (lane 4, Fig. 4B), pre-treatment with LiCl did not
seem to have obvious effects on the DEX-induced inhibition in
either of the cell lines on D6 (lane 8, Fig. 4B). Notice that the
DEX-induced increase in tau phosphorylation was evident on D3
but not on D6 in HEK293/tau441 cells (Fig. 2). Taken together,
the above results suggest that the DEX-induced increase in tau
phosphorylation may mediate the inhibitory effect of DEX in
HEK293/tau441 cells.
5. DEX induces tau-mediated m-calpain activation and
inhibition of calpain activity prevents the negative effects
of DEX in HEK293/tau441 cells
We have shown that the DEX-induced increase in tau
phosphorylation mediated the inhibitory effect of DEX in
HEK293/tau441 cells. According to our hypothesis, we further
determined if m-calpain activation also mediates the inhibitory
effects of DEX, and if so, whether the DEX-induced m-calpain
activation is mediated by tau phosphorylation. Activation of m-
calpain was determined by the ratio of the active/truncated
calpain (78-kDa band) and the inactive/full-length calpain (80-
kDa band). DEX did not affect m-calpain activation in wild-type
HEK293 cells on D3 or on D6 (lane 2, Fig. 5A). DEX did not
affect m-calpain activation in HEK293/tau441 cells on D6 either
(D6, lane 6, Fig. 5A). In contrast, DEX induced an increase in m-
calpain activation in HEK293/tau441 cells on D3 (D3, lane 2,
Fig. 5A). Because the DEX-induced increase in tau phosphory-
lation was evident on D3 (lane 2, Fig. 2), the above results suggest
that the DEX-induced tau phosphorylation may correlate with m-
Figure 4. Effects of LiCl on the DEX-induced inhibitory effect. Both wild-type HEK293 and HEK293/tau441 cells were pre-treated with LiCl
(10 mM, 1 h) and then treated with DEX for 3 days (D3; A) or 6 days (D6; B), followed by stimulation of insulin and Western analysis of pAkt and Akt.
Bars representing means 6 SEM. Pre-treatment with LiCl prevented the inhibitory effect of DEX in HEK293/tau441 cells on D3.
doi:10.1371/journal.pone.0035783.g004
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been shown that m-calpain could result in tau phosphorylation
[49]. To examine whether m-calpain activation mediates the DEX-
induced tau phosphorylation, we pre-treated HEK293/tau441
cells with E-64d (30 mg/ml, 1 h), a cell-membrane-permeable
calpain inhibitor, and then determined the levels of Tau-1 and
total tau by Western blotting. As Fig. 5B shows, pretreatment with
E-64d did not prevent the DEX-induced decrease in Tau-1 in
HEK293/tau441 cells. This suggests that m-calpain may not
mediate the DEX-induced tau phosphorylation. In contrast, pre-
treatment with LiCl (10 mM, 1 h) prevented the DEX-induced m-
calpain activation in HEK293/tau441 cells on D3 (D3, lane 4,
Fig. 5A). Notice that LiCl did not affect m-calpain activation in
HEK293/tau441 cells on D6 or in wild-type HEK293 cells
(Fig. 5A). Because m-calpain activation was observed only in the
tau-expressing HEK293/tau441 cells and prevention of tau
phosphorylation by LiCl inhibited the DEX-induced m-calpain
activation, these results suggest that the DEX-induced tau
phosphorylation mediates m-calpain activation in HEK293/
tau441 cells.
Next we assessed whether the DEX-induced and tau-mediated
m-calpain activation mediates the DEX-induced inhibition on the
insulin-stimulated Akt phosphorylation on D3. However, previous
studies have shown that calpain may inhibit insulin signaling [50–
53]. We also examined how calpain inhibition would affect the
inhibitory effect of DEX on D6, when no activation of m-calpain
was observed upon DEX treatment (D6, lane 2, Fig. 5A). Both cell
lines were pre-treated with E-64d (30 mg/ml, 1 h) and then treated
with DEX for 3 days (D3) or 6 days (D6) (See Materials and Methods).
In wild-type HEK293 cells, E-64d did not affect the insulin-
stimulated increase in pAkt upon DEX treatment on D3 (wild-type
HEK293, D3, lane 6, Fig. 5C) or prevented the inhibitory effect of
DEX on D6 (wild-type HEK293, D6, lane 8, Fig. 5C). In
HEK293/tau441 cells, E-64d did not prevent the inhibitory effect
of DEX on D6 (HEK293/tau441, D6, lane 6, Fig. 5C). Notice the
DEX-induced tau phosphorylation was not evident on D6 (Fig. 2).
On D3, when the DEX-induced tau phosphorylation was evident
(Fig. 2), E-64d prevented the inhibitory effect of DEX (HEK293/
tau441, D3, lane 6, Fig. 5C). These results suggest that the
involvement of m-calpain in the inhibitory effect of DEX may
depend on tau phosphorylation in our system. Taken together, the
above results suggest that the DEX-induced m-calpain activation
may also mediate the inhibitory effect of DEX. Moreover, the
involvement of m-calpain seems to depend on the DEX-induced
tau phosphorylation.
Discussion
In the current study, several observations have been made using
a cellular model system for studying tau pathology, i.e., a HEK293
cell line stably expressing the longest isoform of human tau
(HEK293/tau441 cells). First, DEX increased tau phosphorylation
and induced tau-mediated m-calpain activation. Second, the effects
of DEX on tau phosphorylation and m-calpain activation were
prevented by LiCl pre-treatment. Third, both LiCl pre-treatment
and calpain inhibition by E-64d prevented the DEX-induced
inhibition on the insulin-stimulated Akt phosphorylation.
Numerous potential mechanisms have been proposed to explain
the pathogenic mechanisms of IR [54]. However, these studies
mainly focused in three main targets, i.e., liver, skeletal muscle and
adipose tissue [55,56]. The origin of IR in the context of AD is
difficult to elucidate due to the diverse set of risk factors linked to
AD. Our results suggest that the GCs-induced tau phosphorylation
and consequent m-calpain activation may mediate IR. This
suggests that GCs and IR, two potent driving forces for AD
[4,13], may be linked by tau phosphorylation in the context of AD.
However, neither LiCl nor E-64d prevented the inhibitory effect of
DEX on D6, when the inhibitory effects of DEX were evident in
both cell lines. This suggests that the involvement of the GCs-
induced tau phosphorylation and consequent m-calpain activation
in IR may be only within a particular time window.
Previous rodent studies suggest that IR or lack of insulin
signaling can result in tau hyperphosphorylation [20,57,58].
Indeed, it is generally accepted that insulin activates Akt signaling,
inhibits GSK-3b activity and thus may reduce tau phosphorylation
[45]. It is reasonable to speculate that IR may lead to tau
phosphorylation by activating GSK-3b. However, our results show
that insulin does not affect tau phosphorylation under basal
condition or upon treatment with DEX (Fig. 3). These results
suggest that i) insulin signaling may not affect tau phosphorylation,
and ii) the DEX-induced tau phosphorylation is not mediated by
inhibition of the insulin signaling in our system. In fact, there is a
debate about the relationship with the insulin-activated Akt/GSK-
3b signaling and tau phosphorylation. In brain/neuron-specific
insulin receptor knockout mice, lack of insulin signaling in the
brain activates GSK-3b and leads to tau hyperphosphorylation
[57]. Intriguingly, in high fat diet C57BL6 mice, IR actually
reduces tau phosphorylation at Ser396, Ser202/Thr205 and
Thr231 [59]. Moreover, in C57BL mice, insulin administration
does not affect tau phosphorylation at GSK-3b-relevant sites but
promotes tau phosphorylation at sites that are dependent on
extracelluar regulated kinase [60]. Interestingly, insulin transiently
promotes tau phosphorylation by activating GSK-3b in SH-SY5Y
neuroblastoma cells and primary cortical neurons [46,61].
Furthermore, in C57BL mice intraperitoneally injected with
streptozotocin, which leads to insulin depletion, tau phosphoryla-
tion is mediated by the decrease in protein phosphatase 2A activity
but not by the increase in GSK-3b activity [58]. How lack of
insulin signaling and IR affect tau phosphorylation in vivo and in
AD patients warrants further research. Nevertheless, our study
suggests that i) the GCs-induced tau phosphorylation may not be
mediated by inhibition of insulin signaling, and ii) the GCs-
induced tau phosphorylation could function upstream as a
mediator of IR.
Clinical observations suggest that DM2 is among the risk factors
for AD [5,6,62–64]. Because tau hyperphosphorylation is one of
the key pathological features of AD, our results that the DEX-
induced tau phosphorylation could occur upstream to IR do not
seem to be supported by these clinical data. However, it should be
noticed that tau hyperphosphorylation and the detectable clinical
symptoms of AD are two different notions. Tau hyperpho-
sphorylation may actually occur decades before individuals
manifest clinical symptoms of AD [65]. Tau phosphorylation
may also increase during normal aging [66]. Thus it is not
surprising that tau hyperphosphorylation also occurs in asymp-
tomatic patients with Braak-stage I neuropathology where clinical
symptoms of AD are absent [65]. Because tau hyperphosphoryla-
tion can occur long before the onset of symptoms and may play a
key role in AD pathogenesis and/or progression, it is possible that
tau hyperphosphorylation could contribute to the brain IR in AD.
Because both tau phosphorylation and the prevalence of IR
increases with aging [67], it might be difficult to identify which of
these two events first occurs in brain. It should be also noticed that
brain IR and peripheral IR may be two different pathological
alterations [68]. The extant literature does not resolve whether the
brain IR in AD represents a local disease process, or complica-
tion/extension of peripheral IR, i.e. chronic hyperglycemia,
hyperinsulinemia, and DM2.
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35783Figure 5. Involvement of m-calpain in the inhibitory effect of DEX. A): Both wild-type HEK293 and HEK293/tau441 cells were pre-treated with
LiCl (10 mM, 1 h) and then treated with DEX for 3 days (D3) or 6 days (D6). Activation of m-calpain was determined by the ratios of the active/
truncated calpain (78-kDa bands) and the inactive/full-length calpain (80-kDa bands). Bars representing means 6 SEM. On D3 in HEK293/tau441 cells,
DEX induced m-calpain activation and pre-treatment with LiCl prevented the activation of m-calpain.
*P,0.05 versus control. B): HEK293/tau441 cells
were pre-treated with E-64d (30 mg/ml, 1 h) or LiCl (10 mM, 1 h), and then treated with DEX for 3 days. The level of tau phosphorylation was
determined by the ratio of Tau-1/R134d. Bars representing means 6 SEM. E-64d did not have obvious effect on the DEX-induced increase in tau
phosphorylation.
*P,0.05 versus control,
#P,0.05 between indicated groups. C) Both wild-type HEK293 and HEK293/tau441 cells were pre-treated
with E-64d (30 mg/ml, 1 h) and then treated with DEX for 3 days (D3) or 6 days (D6), followed by stimulation of insulin and Western analysis of pAkt
and Akt. Bars representing means 6 SEM. Pre-treatment with E-64d prevented the inhibitory effect of DEX in HEK293/tau441 cells on D3.
*P,0.05
versus control.
doi:10.1371/journal.pone.0035783.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35783Although the inhibitory effects of DEX were evident in both cell
lines on D6, calpain inhibition did not prevent the inhibitory
effects in either of the cell lines (Fig. 5C). In contrast, calpain
inhibition prevented the inhibitory effect of DEX only on D3,
when the DEX-induced tau phosphorylation was evident (Fig. 2
and Fig. 5C). These results suggest that the involvement of m-
calpain in the GCs-induced IR may not be a universal
phenomenom and the action of m-calpain seems to depend on
the GCs-induced tau phosphorylation. The roles of calpains in the
pathogenesis of IR and DM2 have been extensively studied
[28,29,30,31]. Although Calpain 10 is the first identified diabetes
gene through a genome scan [69]., little is known about its
protease activity and physiological functions [70]. Furthermore,
whether calpain 10 really links with IR and DM2 is still in
controversy [70–72]. Some recent studies have suggested that m-
calpain activation may contribute to the inhibition of insulin
signaling. For instance, m-calpain cleaves phosphoinositide 3-
kinases (PI3Ks), an important upstream activator of Akt, and
reduces PI3Ks enzymatic activities in NIH 3T3 cells [53].
Moreover, m-calpain degrades insulin receptor substrates (IRS),
major substrates of insulin signaling, in human neuroblastoma cells
and prostate epithelial cells [50,52]. Furthermore, calpain
activation by calcium incubation reduced total amount of Akt
and heat shock protein 90, a key Akt regulator protein, in rats
skeletal muscle cells [51]. Although these studies suggest that m-
calpain activation may mediate IR, other studies also show
contradictory results. For instance, calpain inhibition by over-
expression of calpastatin (the endogenous calpain inhibitor)
induced a decrease in Akt level and subsequent IR in mice [73].
Moreover, in soleus muscle strips and adipocytes and adipocytes
isolated from Wistar rats, calpain inhibition by E-64d reduced
insulin-mediated signaling [74]. Furthermore, in 3T3-L1 adipo-
cytes and HepG2 hepatoma cells, inhibition of calpain did not
affect the insulin-mediated PI3K/Akt pathway but it did prevent
the insulin-stimulated glucose uptake [75,76]. These studies
suggest that the roles of m-calpain in IR may be tissue-specific.
Our results suggest that the involvement of m-calpain in IR, at least
in tau-expressing tissues, may depend on the GCs-induced tau
phosphorylation.
However, how the GCs-induced tau phosphorylation mediates
m-calpain activation is not known. The activation and regulation of
calpain activity in vivo is not well understood, although it is a
ubiquitously expressed protein with limited proteolytic activity and
therefore it is assumed to be tightly regulated [77]. We found an
enhanced co-localization of phosphorylated tau and m-calpain in
HEK293/tau441 and SH-SY5Y cells upon DEX treatment
(unpublished data). We speculate that the GCs-induced tau
phosphorylation may enhance the structural link between tau
and m-calpain and thus mediate the activation of m-calpain.
Interestingly, in a postmortem study of AD patients’ brains, it was
found that the hyperphosphorylated tau can bind with a calcium-
binding protein—EF hand domain protein 2, which may be
involved in modification of calpain activity [78].
In conclusion, we have demonstrated that the GCs-induced tau
phosphorylation and consequent m-calpain activation may con-
tribute to IR. Our study suggests that tau phosphorylation and m-
calpain activation may be two key events that link GCs, IR and
AD.
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